Abstract:Introduction. Triple negative breast cancer (TNBC), representing 10-15% of all diagnosed breast cancer (BC) cases, is the most aggressive BC subtype and has higher recurrence rates and therapy resistance. It typically has an inflamed tumor microenvironment and relatively high tumor infiltrating lymphocyte levels. However, T cells are typically less activated compared to non-invasive BC. Hence, we hypothesize that local delivery of immunotherapeutics to activate and reinvigorate T cells can restore the anti-tumor immune response. To this end, we have developed an injectable delivery medium to effectively localize immune agonists to activate, expand, and reinvigorate T cells at the site of the tumor. Methods. The naturally occurring polysaccharide chitosan was crosslinked to form a novel injectable hydrogel (XCSgel). For in vivo tumor treatment, 2.5 × 105 E0771 murine breast cancer cells were implanted subcutaneously on the right flank of C57BL/6 mice. When tumors grew to be 50-100mm3, 5ug and 20ug of interleukin-12 (IL-12) co-formulated in 50uL of XCSgel was delivered intratumorally, with additional treatment groups of 5ug IL-12 in saline, XCSgel alone, and an untreated control. For re-challenge studies, 2.5 × 105 E0771 murine breast cancer cells were implanted subcutaneously on the left flank of mice, with a naïve cohort as a control. For the second tumor study to reinvigorate T cells in mice with larger tumor burdens, 5 × 105 E0771 murine breast cancer cells were implanted subcutaneously on the right flank of C57BL/6 mice. When tumors reach 100-150mm3, 5ug IL-12 in XCSgel, 20ug IL-10 in XCSgel, 5ug IL-12 + 20ug IL-10 in XCSgel, 5ug IL-12 + 20ug IL-10 in saline, and XCSgel will be delivered intratumorally, with an untreated control. Tumor sizes and Kaplan-Meier survival curves were/will be collected across all cohorts. All experiments involving laboratory animals were approved by the Institutional Animal Care and Use Committee at North Carolina State University. Results and Discussion. In the first tumor study, 5ug IL-12 in XCSgel eliminated tumors in 5/5 mice, while 20ug IL-12 in XCSgel eliminated tumors in 4/5 mice and IL-12 in saline eliminated 2/5 tumors. No tumor delay or elimination was observed in untreated and gel alone groups. Upon re-challenge, 5/5 mice in the 5ug IL-12 in XCSgel remained tumor-free over 40 days post-re-challenge, as did 3/4 of the 20ug in XCSgel and 2/2 in IL-12 saline treatment groups. The second intratumoral study is ongoing. Conclusions. A single injection of IL-12 formulated in a novel injectable hydrogel was found to eliminate tumors and stimulate immune memory in a murine triple negative breast cancer model. Results from localized IL-12 and IL-10 cytokine treatment of tumors with larger tumor burdens are ongoing. Given the ability of this localized immunotherapy to induce systemic antitumor immunity, it deserves further consideration as a neoadjuvant treatment prior to breast conserving surgery.Acknowledgements. This work is supported by the NSF Graduate Research Fellowship. Citation Format: Siena M Mantooth, David A Zaharoff. Localized cytokine immunotherapy with a novel injectable hydrogel confers immune memory in murine triple negative breast cancer tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr B031.

Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity

Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade

Low-frequency ultrasound-mediated cytokine transfection enhances T cell recruitment at local and distant tumor sites

Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.

Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

Abstract B031: Localized cytokine immunotherapy with a novel injectable hydrogel confers immune memory in murine triple negative breast cancer tumors

Localized CD47 blockade enhances immunotherapy for murine melanoma

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment

Local Irradiation Sensitized Tumors to Adoptive T Cell Therapy via Enhancing the Cross-Priming, Homing, and Cytotoxicity of Antigen-Specific CD8 T Cells

Next-generation Anti-Pd-l1/il-15 Immunocytokine Elicits Superior Antitumor Immunity in Cold Tumors with Minimal Toxicity

Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens.

Localized ablative immunotherapy drives de novo CD8 + T-cell responses to poorly immunogenic tumors